Omeprazole: a new drug for the treatment of acid-peptic diseases

GARY W. FALK, MD

Omeprazole is the first of a new class of gastric antisecretory drugs, proton pump inhibitors. It inhibits the H⁺,K⁺-adenosinotriphosphatase enzyme of the gastric parietal cell, resulting in potent, long-lasting suppression of basal and stimulated acid secretion. The drug is currently approved for treatment of gastroesophageal reflux disease and Zollinger-Ellison syndrome. In clinical trials, treatment with omeprazole results in rapid healing of duodenal ulcers; it is also effective in treating gastric ulcer disease. It is uniformly well tolerated without significant adverse effects, although animal studies linked profound long-term suppression of gastric acid secretion with the development of gastric carcinoids. Potential future uses include the prophylaxis of ulceration secondary to stress or use of nonsteroidal anti-inflammatory drugs, and the prophylaxis of recurrent peptic ulcer disease.

INDEX TERMS: OMEPRAZOLE, CLINICAL PHARMACOLOGY • CLEVE CLIN J MED 1991; 58:418-427

Editor's note: On June 19, 1991, omeprazole received US Food and Drug Administration approval for the short-term treatment of active duodenal ulcer disease.

OMEPRAZOLE is the first of a new class of drugs, proton pump inhibitors, to be made available for the treatment of diseases in which acid-peptic injury plays a role. It produces more complete and longer-lasting suppression of gastric acid secretion than the histamine-2-receptor (H₂-receptor) antagonists, which have for years been the mainstay in the therapy of acid-peptic disorders. Omeprazole is currently approved by the Food and Drug Administration (FDA) for short-term treatment of erosive esophagitis and symptomatic gastroesophageal reflux which is resistant to standard medical therapy, as well as for the long-term treatment of pathological hypersecretory states such as Zollinger-Ellison syndrome and systemic mastocytosis.

CLINICAL PHARMACOLOGY OF OMEPRAZOLE

Physiology of gastric acid secretion

Acid secretion takes place in the parietal cells of the stomach, which are located in the oxyntic glands of the fundus and corpus. These cells may be stimulated to secrete acid by three different pathways. The neurocrine pathway involves the vagal release of acetylcholine, the paracrine pathway is mediated by the release of histamine from mast cells and enterochromaffin-like (ECL) cells in the stomach, and the endocrine pathway is mediated by the release of gastrin. Each of these transmitters has a specific receptor located on the basolateral surface of the parietal cell (Figure 1). Stimulation of these receptors leads to...
activation of intracellular second messenger systems: histamine stimulates the production of cyclic adenosine monophosphate (cyclic AMP), while gastrin and acetylcholine promote the accumulation of intracellular calcium. These intracellular messengers then activate cyclic AMP-dependent and calcium-dependent protein kinases, which then stimulate the gastric proton pump (the H⁺,K⁺-ATPase enzyme located at the apical surface of the parietal cell) to secrete hydrogen ions in exchange for potassium ions.

**Mechanism of antisecretory activity**

Omeprazole is a substituted benzimidazole (Figure 2). It inhibits the H⁺,K⁺-ATPase enzyme, thus blocking the final step of gastric acid secretion, regardless of the type of stimulation. This mechanism of action is very different from that of the commonly used H₂-receptor antagonists that reduce gastric acid secretion by inhibiting the H₂ receptor located on the basolateral membrane of the parietal cell.

Omeprazole is a weak base. This allows it to accumulate in the acidic environment of the parietal cell secretory canaliculus, where it is protonated and transformed into its active form, a sulphenamide derivative. This compound then reacts with sulphydryl groups on the H⁺,K⁺-ATPase enzyme, forming an inhibitory complex (Figure 3). Omeprazole binds irreversibly to the enzyme, resulting in long-lasting inhibition of gastric acid secretion (to restore gastric secretory activity, new enzyme must be synthesized). Because omeprazole acts at the final step of gastric acid secretion, it inhibits both basal and stimulated acid secretion.

Omeprazole's action is dose-dependent. Oral administration in single doses of 20, 40, 60, or 80 mg inhibited pentagastrin-stimulated gastric acid secretion by 36%, 63%, 90%, and 99% respectively. Single oral doses of 20, 40, or 60 mg inhibited basal acid output by 29%, 81%, and 98%, respectively. Doses of 10, 20, and 30 mg once daily for 1 week resulted in a decrease of 37%, 90%, and 97% in the 24-hour intragastric acidity of nine asymptomatic duodenal ulcer patients.

With repeated oral doses, the antisecretory effects increase progressively during the first 3 to 5 days of drug administration. In all likelihood, this is because the reduction of intragastric acidity decreases the degradation of the drug; thus it enhances its own bioavailability.

The duration of inhibition of acid secretion with omeprazole is long and dose-related. Twenty-four hours after single doses of 20 and 40 mg, pentagastrin-stimulated acid output was decreased by 26% and 48%, respectively; 3 days after the 40-mg dose, a 34% decrease in acid secretion was still seen. Another group of patients was given 30 to 60 mg daily for 14 days. One week after completing the regimen, 24-hour intragastric acidity was decreased by 26%, with normalization seen at 8 weeks.

**Pharmacokinetics**

Omeprazole is acid-labile and is formulated as enteric-coated granules in a hard gelatin capsule. Absorption is
rapid: peak plasma levels are reached 1 to 3 hours after oral administration. Because first-pass hepatic metabolism is extensive, bioavailability after a single oral dose is only 35%, although this may increase to 60% with repeated doses. As mentioned above, this increase coincides with the decrease in gastric acidity and probably reflects improved absorption due to this decrease.

Drug elimination is rapid (half-life is 0.5 to 1 hour). While the degree of acid suppression is unrelated to plasma concentration, it does correlate with the area under the plasma concentration time curve, which reflects the amount of drug available to the parietal cell. Omeprazole is completely metabolized in the liver. The metabolites are inactive and are excreted in the urine (80%) and feces (20%). The elimination of omeprazole metabolites is unaffected by impaired renal function but is decreased somewhat in elderly patients. In patients with impaired hepatic function, bioavailability is close to 100%. The clinical significance of variability in metabolite elimination and bioavailability is uncertain, and no recommendations regarding dose alteration have been made for these patient populations.

SAFETY

Drug interactions

Omeprazole inhibits several monoxygenase reactions which are mediated by enzymes of the cytochrome P450 system (a family of enzymes in the liver involved in the oxidative metabolism of most drugs). Inhibition of these reactions impairs hepatic metabolism of diazepam, phenytoin, and warfarin. Therefore, coadministration of omeprazole with these drugs should be done with care. Omeprazole also selectively induces a subfamily of cytochrome P450 which is involved in the metabolism of acetaminophen and polycyclic hydrocarbons. Theoretically, this could increase the possibility of hepatotoxicity due to acetaminophen, and therefore some physicians advise care in administering omeprazole with acetaminophen. More clinical data are required to clarify this issue. Omeprazole may also interfere with the absorption of drugs that require intragastric acidity for absorption, such as ketoconazole and iron salts.

Adverse effects

In trials involving more than 13,000 patients, omeprazole has been well tolerated. Serious adverse events were reported in 1% of patients, which is no more than with H₂-receptor antagonists or with placebo. Minor symptoms such as nausea, diarrhea, headaches, dyspepsia, and dizziness have been described, but these also are no different from symptoms seen in patients receiving placebo or H₂-receptor antagonists. In addition, the adverse events observed do not increase with age and dose.
Carcinoid tumors

Initial enthusiasm over the potential applications of omeprazole was tempered by the discovery of gastric carcinoid tumors in rats that had been exposed to lifelong high doses of omeprazole. The rats were treated over a 2-year period with 400 μmol/kg of omeprazole (a far greater dose than is used to treat acid-peptic disorders in humans). Results showed that 10% of the male rats and 40% of the female rats developed carcinoid tumors in the stomach. The tumors consisted of ECL endocrine cells and appeared to progress in a continuum from diffuse ECL-cell hyperplasia to focal hyperplasia to focal carcinoids. The finding of carcinoid tumors in rats appears to be species-specific, as similar results have not been seen in other experimental models, such as the mouse or the dog.

It appears that the development of these carcinoid tumors is not directly caused by omeprazole, but is related instead to a marked elevation in serum gastrin. Under normal conditions, gastrin release is inhibited by intragastric acidity, but the reduction of intragastric acidity caused by omeprazole results in the loss of this normal feedback inhibition.

In the rat, elevated gastrin levels (whether caused by omeprazole, high-dose ranitidine, or exogenous administration of gastrin) correlate with an increase in the proliferation rate and density of ECL cells in the stomach. The ECL-cell changes are reversible: ECL-cell density returned to normal 20 weeks after cessation of therapy. When the rats were antrectomized, thus eliminating the major endogenous source of gastrin, administration of omeprazole did not elevate plasma gastrin levels or increase ECL-cell density and proliferation rates, as compared with intact animals.

In humans, gastric carcinoids are rare, accounting for only 3% to 5% of all gastrointestinal carcinoids and 0.3% of gastric tumors. Gastric carcinoid tumors have been seen in patients with Zollinger-Ellison syndrome and pernicious anemia, two naturally occurring states of hypergastrinemia. As in the animal model, ECL-cell density is related to serum gastrin levels in patients with atrophic gastritis, with the highest gastrin levels found in patients with carcinoid tumors. This has led to the investigation of whether omeprazole influences gastrin levels and ECL-cell density in humans. In short-term studies, omeprazole increases fasting serum gastrin levels and 24-hour gastrin profiles to approximately two to five times pretreatment values. The gastrin levels then return to normal within 2 weeks of completion of therapy.

Longer-term studies of the effect of omeprazole on serum gastrin have yielded conflicting results. In a 1-year study, Koop found no increase in gastrin levels beyond a 3.6-fold rise seen after 1 month. Lambers found that gastrin levels increased significantly over the first 6 months of therapy, followed by no further increase for up to 2 years. Jansen described a continued trend of further increases in gastrin over 2 years.

In each of these studies, the greatest increase in gastrin level was in the first month of treatment, and correlated with the gastrin level prior to starting treatment when this information was available. To put the gastrin data in perspective, patients with pernicious anemia have a 24-hour gastrin profile 30 times higher than untreated duodenal ulcer patients, while 28 days of omeprazole treatment increases the 24-hour gastrin profile only five times. Limited data are available on the effect of omeprazole on ECL-cell density in humans. In a short-term study, no significant increase in ECL-cell density was seen in a group of duodenal ulcer patients treated with omeprazole for 4 weeks. In a 2-year study, the ECL-cell density increased during the first year of treatment in 10 patients without a further increase in the ensuing year. However, this finding could not be confirmed in a larger group of patients.

The above animal and human data suggest that the extent and duration of acid suppression are the crucial determinants for the development of gastric carcinoids. There have been no reports of gastric carcinoids with omeprazole in the short-term treatment of acid-peptic diseases, and the short-term use of omeprazole in patients with peptic ulcer disease or gastroesophageal reflux disease does not seem to present a problem. However, the risks associated with continuous long-term omeprazole treatment in humans is not known at this time. It is therefore prudent to monitor serum gastrin levels in patients receiving chronic therapy with omeprazole, and to discontinue or reduce therapy if gastrin levels increase above five times the upper limit of normal.

Gastroesophageal reflux disease

While H₂-receptor antagonists consistently improve the symptoms of gastroesophageal reflux disease, the efficacy of these agents in the healing of erosive and ulcerative esophagitis is less clear. This class of drugs is of uniform benefit in the healing of peptic ulcer disease, but they heal no more than 60% of patients with...
Not all studies showed the same level of benefit. For example, in some studies, 10% to 15% of patients did not show any advantage over the lower doses. Each of these factors must be considered when choosing a treatment plan.

While the healing of macroscopic esophagitis with omeprazole is striking, this benefit is not seen in all patients. In most studies, 10% to 15% of patients do not heal with omeprazole. A major factor influencing healing is the initial severity of the esophagitis. In Hetzel's multicenter study, the healing rate of patients with circumferential ulceration (the most severe grade of esophagitis) was only 44% after 4 weeks of treatment with omeprazole 40 mg and 56% at 8 weeks. Omeprazole is also effective in healing reflux esophagitis refractory to standard-dose H2-receptor antagonist therapy. In a study of 98 patients with erosive esophagitis that was unhealed after 12 weeks of standard-dose therapy with cimetidine or ranitidine, omeprazole therapy (40 mg once daily) healed 90% of patients, compared with 47% of patients on high-dose ranitidine therapy (300 mg twice a day) (P<0.0001).

Although omeprazole appears to be promising in the treatment of gastroesophageal reflux disease, successful therapy has not improved the high relapse rate typically seen after cessation of treatment. An endoscopic relapse rate of 82% was seen 6 months after healing of erosive esophagitis in the multicenter study. Long-term maintenance therapy with full-dose omeprazole has been studied in a limited number of patients in open uncontrolled trials. Omeprazole 20 mg once daily for 12 months in endoscopically healed patients has resulted in relapse rates of 26% to 34%. The eventual role of omeprazole in the long-term maintenance therapy of gastroesophageal reflux disease is undergoing further study, and recommendations await additional data.

Omeprazole is superior to conventional doses of H2-receptor antagonists in the relief of symptoms and healing of mucosal lesions in gastroesophageal reflux disease. With the advent of omeprazole, multi-drug therapy for gastroesophageal reflux disease may no longer be warranted.

Presently, omeprazole is approved by the FDA for 4 to 8 weeks of treatment of erosive or ulcerative esophagitis, or gastroesophageal reflux disease refractory to conventional therapy with H2-receptor antagonists. Practical issues still unresolved include the safety of long-term treatment and, given the high relapse rate of esophagitis, the appropriate intervals for retreatment.

---

**TABLE 1**

HEALING RATES FOR OMEPRAZOLE IN GASTROESOPHAGEAL REFUX DISEASE: RESULTS OF CONTROLLED TRIALS

<table>
<thead>
<tr>
<th>Source</th>
<th>N</th>
<th>Regimen</th>
<th>Dosage</th>
<th>% Healing</th>
<th>4 wk</th>
<th>6 wk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Klinkenberg-Knol30(1987)</td>
<td>25</td>
<td>Omeprazole</td>
<td>60 mg</td>
<td>76*</td>
<td>88†</td>
<td></td>
</tr>
<tr>
<td></td>
<td>26</td>
<td>Ranitidine</td>
<td>150 mg bid</td>
<td>27</td>
<td>38</td>
<td></td>
</tr>
<tr>
<td>Vantrappen31(1988)</td>
<td>26</td>
<td>Omeprazole</td>
<td>40 mg</td>
<td>85‡</td>
<td>96‡</td>
<td></td>
</tr>
<tr>
<td></td>
<td>25</td>
<td>Ranitidine</td>
<td>150 mg bid</td>
<td>40</td>
<td>52</td>
<td></td>
</tr>
<tr>
<td>Havelund32(1988)</td>
<td>46</td>
<td>Omeprazole</td>
<td>40 mg</td>
<td>70§</td>
<td>85§</td>
<td></td>
</tr>
<tr>
<td></td>
<td>42</td>
<td>Ranitidine</td>
<td>150 mg bid</td>
<td>26</td>
<td>44</td>
<td></td>
</tr>
<tr>
<td>Sandmark33(1988)</td>
<td>69</td>
<td>Omeprazole</td>
<td>20 mg</td>
<td>67¶</td>
<td>85¶</td>
<td></td>
</tr>
<tr>
<td></td>
<td>75</td>
<td>Ranitidine</td>
<td>150 mg bid</td>
<td>31</td>
<td>50</td>
<td></td>
</tr>
<tr>
<td>Hetzel29(1988)</td>
<td>31</td>
<td>Omeprazole</td>
<td>20 mg/40mg</td>
<td>81¶</td>
<td>81¶</td>
<td></td>
</tr>
<tr>
<td></td>
<td>32</td>
<td>Placebo</td>
<td></td>
<td>6</td>
<td>9</td>
<td></td>
</tr>
</tbody>
</table>

*P<0.002 †P<0.001 ‡P<0.01 †P not given §P<0.0001.

---

macroscopic esophagitis. Patients with severe gastroesophageal reflux disease are often treated with multiple medications for prolonged periods of time at considerable expense, and when this therapy fails, antireflux surgery is often necessary.

Omeprazole markedly decreased 24-hour acid exposure in a group of 12 patients with erosive esophagitis. Prior to treatment, esophageal pH was <4.13.9% of the time in the upright position, 13.0% of the time in the supine position, and 14.1% of the time over the entire 24-hour period. After 3 weeks of therapy with omeprazole 20 mg daily, the corresponding values were significantly decreased to normal 24-hour acid exposure (2.5%, 0.1%, and 2.5%, respectively).

The efficacy of omeprazole in the treatment of gastroesophageal reflux disease has been studied in controlled clinical trials of patients with erosive or ulcerative esophagitis (Table 1). At doses of 20 or 40 mg once daily, omeprazole is clearly superior to placebo in the healing of erosive or ulcerative esophagitis. At doses of 20, 40, and 60 mg, omeprazole is statistically superior to the H2-receptor antagonist ranitidine after 4 or 8 weeks of therapy, but the 60-mg dose does not appear to offer any advantage over the lower doses. Each of these studies also demonstrated a rapid and profound improvement in symptoms of gastroesophageal reflux disease (heartburn, regurgitation, and dysphagia) in comparison to the control agents. After 4 weeks of therapy, up to 85% of omeprazole-treated patients had no heartburn, compared with up to 42% of the ranitidine-treated patients.31,33

While the healing of macroscopic esophagitis with omeprazole is striking, this benefit is not seen in all patients. In most studies, 10% to 15% of patients do not heal with omeprazole.
### TABLE 2
HEALING RATES FOR OMEPRAZOLE IN DUODENAL ULCER DISEASE: RESULTS OF COMPARISON STUDIES

<table>
<thead>
<tr>
<th>Source</th>
<th>N</th>
<th>Drug</th>
<th>Dosage</th>
<th>2 wk</th>
<th>4 wk</th>
<th>6 wk</th>
<th>8 wk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Classen45 (1985)</td>
<td>146</td>
<td>Omeprazole</td>
<td>20 mg</td>
<td>72*</td>
<td>96</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>160</td>
<td>Ranitidine</td>
<td>150 mg bid</td>
<td>59</td>
<td>92</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Lauritsen46 (1985)</td>
<td>67</td>
<td>Omeprazole</td>
<td>30 mg</td>
<td>73*</td>
<td>92*</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>65</td>
<td>Cimetidine</td>
<td>1g</td>
<td>46</td>
<td>74</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Bardhan47 (1986)</td>
<td>34</td>
<td>Omeprazole</td>
<td>20 mg</td>
<td>83*</td>
<td>94*</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>36</td>
<td>Omeprazole</td>
<td>40 mg</td>
<td>83*</td>
<td>100</td>
<td>—</td>
<td>100</td>
</tr>
<tr>
<td></td>
<td>35</td>
<td>Ranitidine</td>
<td>150 mg bid</td>
<td>53</td>
<td>82</td>
<td>—</td>
<td>94</td>
</tr>
<tr>
<td>Barbano48 (1987)</td>
<td>61</td>
<td>Omeprazole</td>
<td>20 mg</td>
<td>66</td>
<td>97*</td>
<td>100*</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>60</td>
<td>Ranitidine</td>
<td>150 mg bid</td>
<td>53</td>
<td>85</td>
<td>92</td>
<td>—</td>
</tr>
<tr>
<td>Archambault49 (1988)</td>
<td>85</td>
<td>Omeprazole</td>
<td>20 mg</td>
<td>58</td>
<td>84</td>
<td>88</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>84</td>
<td>Cimetidine</td>
<td>600 mg bid</td>
<td>46</td>
<td>80</td>
<td>89</td>
<td>—</td>
</tr>
<tr>
<td>Marks50 (1988)</td>
<td>69</td>
<td>Omeprazole</td>
<td>20 mg</td>
<td>65*</td>
<td>97*</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>66</td>
<td>Ranitidine</td>
<td>300 mg</td>
<td>39</td>
<td>81</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Mulder51 (1989)</td>
<td>91</td>
<td>Omeprazole</td>
<td>20 mg</td>
<td>63</td>
<td>91</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>90</td>
<td>Ranitidine</td>
<td>150 mg bid</td>
<td>65</td>
<td>96</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Cooperative Study Group53 (1990)</td>
<td>94</td>
<td>Omeprazole</td>
<td>40 mg</td>
<td>68*</td>
<td>99*</td>
<td>—</td>
<td>100</td>
</tr>
<tr>
<td></td>
<td>94</td>
<td>Ranitidine</td>
<td>150 mg bid</td>
<td>48</td>
<td>88</td>
<td>97</td>
<td>—</td>
</tr>
<tr>
<td>McFarland52 (1990)</td>
<td>125</td>
<td>Omeprazole</td>
<td>20 mg</td>
<td>70*</td>
<td>91*</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>122</td>
<td>Ranitidine</td>
<td>300 mg</td>
<td>61</td>
<td>80</td>
<td>—</td>
<td>—</td>
</tr>
</tbody>
</table>

*P<0.05  tP<0.01  §P=0.007  § = "significantly better," P value not given  qP<0.005

**Zollinger-Ellison syndrome**

Zollinger-Ellison syndrome accounts for approximately 0.1% of all patients with duodenal ulcer disease in the United States. It is characterized by gastric acid hypersecretion due to a gastrin-producing tumor (typically located in the pancreas or duodenum or, on occasion, at distant sites) and results in many symptoms and complications: 90% of patients develop ulceration of the upper gastrointestinal tract, while other less frequent symptoms include diarrhea and heartburn.

Control of gastric acid hypersecretion is central to the management of Zollinger-Ellison syndrome. This was formerly accomplished by total gastrectomy until the advent of H₂-receptor antagonists, which are highly effective in treating gastric acid hypersecretion. However, large doses are often needed at frequent intervals, and the amount of drug required for treatment often increases with time.

In Zollinger-Ellison syndrome, acute therapy with omeprazole results in a profound decrease in gastric acid secretion. In 11 patients treated with a single 60-mg dose of omeprazole, acid secretion was inhibited by 50% at 3 hours, 78% at 4 hours, and 86% at 8 hours after administration. Gastric acid secretion was still inhibited by 80% at 24 hours after administration of omeprazole and by 50% at 48 hours after cessation of chronic therapy.

Chronic therapy with omeprazole for up to 5 years has uniformly resulted in continued inhibition of acid secretion, good symptom control, complete healing of any mucosal lesions, and lack of adverse effects. In the largest study of the long-term efficacy of omeprazole in the treatment of Zollinger-Ellison syndrome, 40 patients followed for up to 51 months required an average dose of 82.5 mg daily to control acid secretion. Only 6 patients required an increase in dosage during the study and 9 patients required twice-daily dosing. The low incidence of tachyphylaxis has been confirmed in other studies, as dose requirements for most patients remain stable over time.

Treatment of Zollinger-Ellison syndrome with omeprazole does not result in further elevation of gastrin levels.

Thus, omeprazole should be regarded as the drug of choice for the therapy of gastric acid hypersecretion seen in Zollinger-Ellison syndrome. It is safe and effective and has the advantage of requiring fewer pills and dose-adjustments than H₂-receptor antagonists. The initial dose is typically 60 mg daily, which should then be titrated to a basal acid output (24 hours after the last dose) of <10 mEq per hour.
syndrome, symptoms alone are an unreliable guide to assess control of gastric acid secretion, and the presence of gastrointestinal pathology correlates with gastric acid secretion rates >10 mEq per hour. An intravenous formulation will soon be available for the perioperative control of acid secretion in Zollinger-Ellison syndrome patients.

Duodenal ulcer disease

H₂-receptor antagonists are the current mainstay of therapy for duodenal ulcer disease. They are well tolerated and, on average, heal 51%, 78%, and 92% of ulcers after 2, 4, and 8 weeks of therapy. In randomized, controlled trials comparing omeprazole to standard doses of cimetidine or ranitidine, omeprazole is superior or equivalent in duodenal ulcer healing. The results of these trials are summarized in Table 2. Omeprazole has resulted in healing rates of 63% to 83% at 2 weeks and 91% to 100% at 4 weeks compared with healing rates of 46% to 65% at 2 weeks and 74% to 96% at 4 weeks with ranitidine or cimetidine. Thus, omeprazole achieves healing rates at 4 weeks that are typically seen at 8 weeks with H₂-receptor antagonists. A daily 20-mg dose of omeprazole was used in most of these studies, and increasing the dose to 40 mg did not offer any therapeutic advantage.

Healing rates for omeprazole are lower in North American studies than in studies performed overseas. In the US study, the healing rate was 41% at 2 weeks and 75% at 4 weeks, whereas in a Canadian study the healing rates were 54% and 84% at the same time intervals. This is in contrast to the typical healing rate of better than 90% at 4 weeks seen in overseas trials. The reason for this difference is unknown.

In addition to accelerating the healing of duodenal ulcers, omeprazole typically relieves symptoms more rapidly than H₂-receptor antagonists, but its impact on symptom relief is more variable than that seen with healing.

Despite the more profound suppression of acid secretion seen with omeprazole, duodenal ulcer relapse rates are no different than those seen after treatment with the H₂-receptor antagonists.

The optimal dose and duration of omeprazole treatment in duodenal ulcer disease has yet to be determined but appears to be 20 mg once a day for 4 weeks. Increasing the dose to 40 mg may be useful in the treatment of ulcers refractory to conventional doses of H₂-receptor antagonists, although more data are needed. For typical duodenal ulcers, omeprazole may offer a modest advantage over conventional therapy at 4 weeks. Omeprazole has not yet received FDA approval for this indication.

Gastric ulcer disease

The results of trials comparing omeprazole to H₂-receptor antagonists in the treatment of gastric ulcers are summarized in Table 3. Inhibition of acid secretion with H₂-receptor antagonists results in average healing rates of 63%, 75%, and 88% after 4, 6, and 8 weeks of treatment. In three of the five studies, healing rates achieved with omeprazole are equivalent but not superior to those seen with H₂-receptor antagonists.

In two trials, omeprazole at a dose of 20 mg once daily was superior to H₂-receptor antagonists at 4 weeks, but no differences were seen at 8 weeks. In a study of 602 patients, Walan and associates demonstrated healing at 4 weeks in 69%, 80%, and 59% of patients treated with omeprazole 20 mg once daily, omeprazole 40 mg once daily, and ranitidine 150 mg twice daily, and in 89%, 96%, and 85% of patients at 8 weeks. Omeprazole, 40 mg once daily was superior to the other regimens at both time intervals, and the 20-mg dose was superior to ranitidine at 4 weeks only. This study also showed that these differences in healing were maintained in those patients receiving concurrent therapy with nonsteroidal anti-inflammatory drugs (NSAIDs).

In three of the comparison trials, relief of ulcer symptoms was more rapid in the omeprazole-treated patients, while no difference in symptom relief was seen in the other studies. Recurrence rates of ulcers within 6 months of therapy are no different in patients treated with omeprazole or ranitidine. As in other indications, omeprazole treatment has been uniformly well tolerated, with no reports of any significant adverse effects.

The efficacy of omeprazole in the treatment of gastric ulcer disease is less impressive than that seen in the other indications. The benefit of omeprazole in patients undergoing concurrent therapy with NSAIDs is of special clinical interest, but further trials are necessary. The role (if any) of omeprazole in gastric ulcer disease awaits the results of additional studies.

Resistant peptic ulcer disease

The role of omeprazole in the treatment of peptic ulcer disease resistant to conventional doses of H₂-receptor antagonists has been examined in open studies and in a limited number of controlled tri-
TABLE 3
HEALING RATES FOR OMEPRAZOLE IN GASTRIC ULCER DISEASE: RESULTS OF COMPARISON STUDIES

<table>
<thead>
<tr>
<th>Source</th>
<th>N</th>
<th>Regimen</th>
<th>Drug</th>
<th>Dosage</th>
<th>2 wk</th>
<th>4 wk</th>
<th>6 wk</th>
<th>8 wk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Classen55 (1985)</td>
<td>83</td>
<td>Omeprazole</td>
<td>20 mg</td>
<td>43</td>
<td>81</td>
<td>—</td>
<td>—</td>
<td>95</td>
</tr>
<tr>
<td></td>
<td>74</td>
<td>Ranitidine</td>
<td>150 mg bid</td>
<td>45</td>
<td>80</td>
<td>—</td>
<td>—</td>
<td>90</td>
</tr>
<tr>
<td>Lauritsen56 (1988)</td>
<td>90</td>
<td>Omeprazole</td>
<td>30 mg</td>
<td>54*</td>
<td>81</td>
<td>86</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>86</td>
<td>Cimetidine</td>
<td>1g</td>
<td>39</td>
<td>73</td>
<td>78</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Walan57 (1989)</td>
<td>203</td>
<td>Omeprazole</td>
<td>20 mg</td>
<td>—</td>
<td>69*</td>
<td>—</td>
<td>—</td>
<td>89</td>
</tr>
<tr>
<td></td>
<td>194</td>
<td>Omeprazole</td>
<td>40 mg</td>
<td>—</td>
<td>80*</td>
<td>—</td>
<td>—</td>
<td>96</td>
</tr>
<tr>
<td></td>
<td>205</td>
<td>Ranitidine</td>
<td>150 mg bid</td>
<td>—</td>
<td>59</td>
<td>—</td>
<td>—</td>
<td>85</td>
</tr>
<tr>
<td>Bate58 (1989)</td>
<td>102</td>
<td>Omeprazole</td>
<td>20 mg</td>
<td>—</td>
<td>73*</td>
<td>—</td>
<td>—</td>
<td>84</td>
</tr>
<tr>
<td></td>
<td>87</td>
<td>Cimetidine</td>
<td>400 mg bid</td>
<td>—</td>
<td>58</td>
<td>—</td>
<td>—</td>
<td>75</td>
</tr>
<tr>
<td>Danish Multicenter59 (1989)</td>
<td>73</td>
<td>Omeprazole</td>
<td>30 mg</td>
<td>41</td>
<td>77</td>
<td>88</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>73</td>
<td>Cimetidine</td>
<td>1g</td>
<td>41</td>
<td>58</td>
<td>82</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Cooperative Study Group51 (1990)</td>
<td>16</td>
<td>Omeprazole</td>
<td>40 mg</td>
<td>—</td>
<td>81</td>
<td>—</td>
<td>—</td>
<td>93</td>
</tr>
<tr>
<td></td>
<td>24</td>
<td>Ranitidine</td>
<td>150 mg bid</td>
<td>—</td>
<td>58</td>
<td>—</td>
<td>—</td>
<td>87</td>
</tr>
</tbody>
</table>

*P<0.05.  †P<0.0005.

CONCLUSIONS AND FUTURE PERSPECTIVES

The ultimate role of omeprazole in the treatment of acid-peptic disorders remains to be determined. Currently approved and potential future clinical applications for omeprazole are listed in Table 4. Omeprazole represents a major advance in the treatment of gastroesophageal reflux disease and Zollinger-Ellison syndrome. Approval can be anticipated for the treatment of duodenal ulcer disease shortly and for gastric ulcer disease over the next several years.

While omeprazole is safe and well tolerated in all short-term studies, uncertainty exists with respect to the long-term consequences of hypergastrinemia caused by profound acid suppression, and additional studies are needed to address this concern.

Weekend or intermittent therapy is an option that is being examined to avoid this problem. Weekend therapy with omeprazole at a dose of 20 mg in a limited number of patients has resulted in either slight or no increase in basal gastrin levels, and slight increases in meal-stimulated gastrin levels after 4 to 8 weeks of therapy. However, after 4 days without treatment, basal and peak acid outputs had reverted to the pretreatment values. No trials examining the clinical efficacy of weekend-only therapy in acid-peptic disorders have been published to date.

Additional clinical applications will undoubtedly come in the areas of prophylaxis of stress-induced gastropathy in critically ill patients, recurrent duodenal ulcer disease, and ulceration induced by NSAIDs. A recent preliminary study with intravenous...
omепрозол in patients with actively bleeding peptic ulcers demonstrated cessation of bleeding in 84% of the omeprazole-treated group, compared with 15% in a group treated with ranitidine (therapy with H₂-receptor antagonists does not appear to be effective in the treatment of actively bleeding peptic ulcers).

References

Esophageal ulceration after endoscopic sclerotherapy of esophageal varices may be resistant to standard therapy with H₂-receptor antagonists and sucralfate. In an open study with omeprazole 40 mg daily in 10 such patients, complete healing was seen in each patient after 8 weeks.

Therapeutic applications of omeprazole in the areas of non-cardiac chest pain and non-ulcer dyspepsia can also be anticipated as efforts continue to examine the role of acid in the pathogenesis of both of these disorders.

Therapy with omeprazole is at present quite expensive. In Cleveland, the wholesale cost of omeprazole is $92 for 30 days of therapy at a dose of 20 mg daily, compared with $56 to $79 for standard doses of H₂-receptor antagonists for the same duration. In spite of the expense, however, omeprazole is clearly more cost-effective than treatment with multiple drugs or higher-than-normal doses of H₂-receptor antagonists in gastroesophageal reflux disease. In duodenal ulcer disease, the shorter course of therapy with omeprazole may prove to be a cost advantage as well.


